RootPath raises USD7m seed round led by Sequoia China
RootPath, a biotechnology company developing a powerful personalised T cell therapy platform that bridges precision medicine and cancer immunotherapy, has closed a USD7 million seed funding round led by Sequoia China with participation from Volcanics Venture, BV (Baidu Ventures) and Nest.Bio Ventures. The company, which was launched in 2017 by

